RXRX
$3.25-0.12 (-3.56%)
Recursion Pharmaceuticals, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industr...
Recent News
Recursion Pharmaceuticals Details AI-Driven Drug Pipeline, Sanofi/Roche Milestones, Runway to 2028
Recursion Pharmaceuticals (NASDAQ:RXRX) Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, recent portfolio decisions, partnership economics, and cash runway during a fireside chat hosted by KeyBank healthcare tech equity analy
Recursion Pharmaceuticals (RXRX) Advances While Market Declines: Some Information for Investors
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.37, indicating a +1.51% shift from the previous trading day.
Jim Cramer on Recursion Pharmaceuticals: “It’s a Let Down, Big Let Down”
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller mentioned that Cathie Wood invested in the stock, Cramer remarked, “That’s, it’s a let down, big let down. Came on the show, talked the big game, didn’t deliver.” Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotech company that uses […]
Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Recursion Pharmaceuticals (RXRX) reached $3.44 at the closing of the latest trading day, reflecting a -1.99% change compared to its last close.
Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1‑Year Share Slump Accurately
If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article will walk you through how its valuation stacks up using several common yardsticks. The stock recently closed at US$3.51, with returns of a 3.3% decline over 7 days, an 11.8% decline over 30 days, a 16.4% decline year to date, and a 42.7% decline over the past year, plus a 54.2% decline over three years. Recent coverage of Recursion has focused on its profile as a...